317 related articles for article (PubMed ID: 32600158)
21. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
25. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
26. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.
Paglino JC; Ozduman K; van den Pol AN
J Virol; 2012 Jul; 86(13):7280-91. PubMed ID: 22553327
[TBL] [Abstract][Full Text] [Related]
27. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
[TBL] [Abstract][Full Text] [Related]
28. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
30. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
31. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
32. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.
Leung EYL; McNeish IA
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452316
[TBL] [Abstract][Full Text] [Related]
33. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
35. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R; Dempe S; Dinsart C; Rommelaere J
Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells.
Angelova A; Pierrard K; Detje CN; Santiago E; Grewenig A; Nüesch JPF; Kalinke U; Ungerechts G; Rommelaere J; Daeffler L
Pathogens; 2023 Apr; 12(4):. PubMed ID: 37111493
[TBL] [Abstract][Full Text] [Related]
38. Viruses for tumor therapy.
Bell J; McFadden G
Cell Host Microbe; 2014 Mar; 15(3):260-5. PubMed ID: 24629333
[TBL] [Abstract][Full Text] [Related]
39. Regression of glioma in rat models by intranasal application of parvovirus h-1.
Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
[TBL] [Abstract][Full Text] [Related]
40. [Oncolytic viruses for therapy of malignant glioma].
Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
